FDA reconfirm efficacy of cholesterol-lowering drugs

The U.S. FDA reaffirmed its stance that high level of LDL or “bad cholesterol,” is key risk factor for heart diseases such as heart attack, stroke etc, and reduction in LDL cholesterol lowers the risk of these diseases. The agency was reviewing of data from ENHANCE, a trial, which was comparing Zocor (HMG-CoA reductase inhibitor), Read more